课题基金 / 基金详情

Cannabinoid Receptors and Novel Antiglaucoma Drugs

Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
批准号:
6923583
负责人:
ZHAO-HUI SONG
金额:
$29.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2007-07-31

项目摘要

项目成果

ZHAO-HUI SONG的其他基金

相似基金

相关文献

中文摘要
翻译
项目描述(由申请人提供):本项目的长期目标是了解大麻素降低眼压(IOP)的机制,为开发新型大麻素提供基础,这些大麻素具有更好的降低眼压的性能,并且没有大麻的精神副作用。在本提案中要测试的中心假设是大麻素作用于流出途径的多个靶点的特定大麻素受体,以发挥其降低iops的作用。为了验证这一假设,计划了以下具体目标。(1)利用最近开发的高亲和力和/或亚型选择性大麻素配体,研究大麻素配体对灌注的人眼前段流出设施的影响和大麻素受体的作用。(2)绘制大麻素受体亚型在小梁网和睫状肌两个大麻素潜在靶点的分布。(3)研究大麻素受体在小梁网和睫状肌细胞中的配体结合特性和信号转导机制。(4)确定大麻素配体、大麻素受体和大麻素信号通路在调节小梁网和纤毛肌细胞功能(如细胞骨架和基质金属蛋白酶)中的作用。分子生物学、细胞生物学和药理学方法的结合将应用于拟议的研究。将尝试将体外实验获得的信息与离体器官灌注研究相关联,以了解大麻素受体的作用以及大麻素对房水流出的影响机制。通过研究大麻素降低眼压作用的机制,本研究可能有助于发现更有效的抗青光眼大麻素配体。通过破译参与大麻素降低眼压作用的特定眼大麻素受体亚型,本研究可能有助于将大麻素期望的降低眼压作用与其不希望的精神活性副作用分开。
英文摘要
DESCRIPTION (provided by applicant): The long-term goal of this project is to understand the mechanisms for cannabinoids to lower intraocular pressure (IOP), and to provide a basis for developing novel cannabinoids with improved IOP-lowering properties, and devoid of psychoactive side-effects of marijuana. The central hypothesis to be tested in this proposal is that cannabinoids act on specific cannabinoid receptors in multiple targets of the outflow pathways to exert their IOP-lowering effects. To test this hypothesis, the following specific aims are planned. (1) To test the effects of cannabinoid ligands and the roles of cannabinoid receptors on outflow facility with perfused human ocular anterior segment, using recently developed high affinity and/or subtype-selective cannabinoid ligands. (2) To map the distribution of cannabinoid receptor subtypes in two potential targets of cannabinoids, trabecular meshwork and ciliary muscle. (3) To characterize ligand binding properties and signal transduction mechanisms of cannabinoid receptors in trabecular meshwork and ciliary muscle cells. (4) To determine the effects of cannabinoid ligands, the roles of cannabinoid receptors, and cannabinoid signaling pathways in regulating the cellular functions (such as cell cytoskeleton and matrix metalloproteases) of trabecular meshwork and ciliary muscle cells. A combination of molecular biology, cell biology and pharmacology approaches will be applied to the proposed research. Attempts will be made to correlate information gained from in vitro experiments with ex vivo organ perfusion studies in order to understand the roles of cannabinoid receptors and the mechanisms for the effects of cannabinoids on aqueous humor outflow. By investigating the mechanisms underlying the IOP-lowering effects of cannabinoids, this study may facilitate the discovery of more effective anti-glaucoma cannabinoid ligands. By deciphering specific ocular cannabinoid receptor subtypes that are involved in the IOP-lowering effects of cannabinoids, this study may help to separate the desired IOP-lowering effects of cannabinoids from their undesired psychoactive side-effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endocannabinoid system as a therapeutic target for PVR
  • 批准号:
    10747004
  • 项目类别:
  • 资助金额:
    $44.53万
  • 财政年份:
    2023
  • 负责人:
    ZHAO-HUI SONG
  • 依托单位:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
  • 批准号:
    7655084
  • 项目类别:
  • 资助金额:
    $37.0万
  • 财政年份:
    2003
  • 负责人:
    ZHAO-HUI SONG
  • 依托单位:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
  • 批准号:
    6774098
  • 项目类别:
  • 资助金额:
    $29.4万
  • 财政年份:
    2003
  • 负责人:
    ZHAO-HUI SONG
  • 依托单位:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
  • 批准号:
    7895529
  • 项目类别:
  • 资助金额:
    $37.0万
  • 财政年份:
    2003
  • 负责人:
    ZHAO-HUI SONG
  • 依托单位:
海外基金